The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammatory cortical demyelination in early multiple sclerosis.
Open accessAbstract
BACKGROUND: Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease. METHODS: We evaluated the prevalence and character of demyelinating cortical lesions in patients with multiple sclerosis. Cortical tissues were obtained in passing during biopsy sampling of white-matter lesions. In most cases, biopsy was done with the use of stereotactic procedures to diagnose suspected tumors. Patients with sufficient cortex (138 of 563 patients screened) were evaluated for cortical demyelination. Using immunohistochemistry, we characterized cortical lesions with respect to demyelinating activity, inflammatory infiltrates, the presence of meningeal inflammation, and a topographic association between cortical demyelination and meningeal inflammation. Diagnoses were ascertained in a subgroup of 77 patients (56%) at the last follow-up visit (at a median of 3.5 years). RESULTS: Cortical demyelination was present in 53 patients (38%) (104 lesions and 222 tissue blocks) and was absent in 85 patients (121 tissue blocks). Twenty-five patients with cortical demyelination had definite multiple sclerosis (81% of 31 patients who underwent long-term follow-up), as did 33 patients without cortical demyelination (72% of 46 patients who underwent long-term follow-up). In representative tissues, 58 of 71 lesions (82%) showed CD3+ T-cell infiltrates, and 32 of 78 lesions (41%) showed macrophage-associated demyelination. Meningeal inflammation was topographically associated with cortical demyelination in patients who had sufficient meningeal tissue for study. CONCLUSIONS: In this cohort of patients with early-stage multiple sclerosis, cortical demyelinating lesions were frequent, inflammatory, and strongly associated with meningeal inflammation. (Funded by the National Multiple Sclerosis Society and the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation (Bo et al., 2004; Brink et al., 2005; van Horssen et al., 2007), although early lesions have been associated with prominent microglial activation (Lucchinetti et al., 2011).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“Biopsies taken from early MS patients with cortical demyelination were more likely to have leptomeningeal inflammation, consisting of effector T cells and IgA B cells infiltrates, than those without cortical demyelination.”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“The leptomeninges are now recognized as a key player in multiple sclerosis (MS), an inflammatory CNS autoimmune disorder characterized by axon demyelination”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMagliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Research works printed but not linked: 1
- Tardif CL, 2010, Med Image Comput Assist Interv, 13, 181
Cited by
Sorted by citations
Items 401–500 of 1,000
Yamamoto, S., Gotoh, M., Kawamura, Y., Yamashina, K., Yagishita, S., Awaji, T., Tanaka, M., Maruyama, K., Murakami‐Murofushi, K., & Yoshikawa, K. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.040 · Cited by 35
Retinal hyperreflecting foci associate with cortical pathology in multiple sclerosis
Pengo, M., Miante, S., Franciotta, S., Ponzano, M., Torresin, T., Bovis, F., Rinaldi, F., Perini, P., Saiani, M., Margoni, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001180 · Cited by 35
Garis, G., Haupts, M. R., Duning, T., & Hildebrandt, H. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06385-1 · Cited by 35
Inflammatory Cortical Demyelination in Early Multiple Sclerosis
Minagar, A. (2012) · Yearbook of Neurology and Neurosurgery · doi:10.1016/j.yneu.2012.04.008 · Cited by 34
Profiles of cortical inflammation in multiple sclerosis by 11 C-PBR28 MR-PET and 7 Tesla imaging
Herranz, E., Louapre, C., Treaba, C. A., Govindarajan, S. T., Ouellette, R., Mangeat, G., Loggia, M. L., Cohen‐Adad, J., Klawiter, E. C., Sloane, J. A., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519867320 · Cited by 34
Fritsche, L., Teuber‐Hanselmann, S., Soub, D., Harnisch, K. J., Mairinger, F. D., & Junker, A. (2019) · Brain Pathology · doi:10.1111/bpa.12800 · Cited by 34
Stromal cell niches in the inflamed central nervous system.
Pikor, N. B., Cupovic, J., Onder, L., Gommerman, J. L., & Ludewig, B. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601566 · Cited by 33
MRI in multiple sclerosis: what is changing?
Filippi, M., Preziosa, P., & Rocca, M. A. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000572 · Cited by 33
Ma, S., Wang, N., Fan, Z., Kaisey, M., Sicotte, N. L., Christodoulou, A., & Li, D. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28553 · Cited by 33
Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-analysis
Joseph, B., Nandakumar, A. L., Ahmed, A. T., Gopal, N., Murad, M. H., Frye, M. A., Tobin, W. O., & Singh, B. (2020) · Evidence-Based Mental Health · doi:10.1136/ebmental-2020-300207 · Cited by 33
Fransen, N. L., de Jong, B. A., Heß, K., Kuhlmann, T., Vincenten, M. C. J., Hamann, J., Huitinga, I., & Smolders, J. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000955 · Cited by 33
Groppa, S., González‐Escamilla, G., Eshaghi, A., Meuth, S. G., & Ciccarelli, O. (2021) · Brain Communications · doi:10.1093/braincomms/fcab237 · Cited by 34
Update on immunopathogenesis and immunotherapy in multiple sclerosis
Hemmer, B., & Selter (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31813 · Cited by 33
LC3, an autophagosome marker, is expressed on oligodendrocytes in Nasu-Hakola disease brains
Satoh, J., Motohashi, N., Kino, Y., Ishida, T., Yagishita, S., Jinnai, K., Arai, N., Nakamagoe, K., Tamaoka, A., Saito, Y., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-68 · Cited by 34
Lee, C., Mak, H. K., Chiu, P.-W., Chang, H., Barkhof, F., & Chan, K. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25866 · Cited by 34
Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity
Lindner, M., Klotz, L., & Wiendl, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14339 · Cited by 33
Khaw, Y. M., Tierney, A., Cunningham, C., Soto-Díaz, K., Kang, E., Steelman, A. J., & Inoue, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017213118 · Cited by 32
MRI outcomes in the diagnosis and disease course of multiple sclerosis
Simon, J. H. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00017-0 · Cited by 33
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
Creeke, P. I., & Farrell, R. A. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612469264 · Cited by 32
Morris, G., Berk, M., & Puri, B. K. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0598-z · Cited by 32
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
Ward, L. A., Lee, D. S. W., Sharma, A. K., Wang, A. A., Naouar, I., Xianjie, I., Pikor, N. B., Nuesslein‐Hildesheim, B., Ramaglia, V., & Gommerman, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.132522 · Cited by 32
MicroRNAs in gray and white matter multiple sclerosis lesions: impact on pathophysiology
Teuber‐Hanselmann, S., Meinl, E., & Junker, A. (2020) · The Journal of Pathology · doi:10.1002/path.5399 · Cited by 32
MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis
Tavazzi, E., Zivadinov, R., Dwyer, M. G., Jakimovski, D., Singhal, T., Weinstock‐Guttman, B., & Bergsland, N. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1757435 · Cited by 33
Disorders of vision in multiple sclerosis
Dhanapalaratnam, R., Markoulli, M. P., & Krishnan, A. V. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1947745 · Cited by 36
Puthenparampil, M., Torresin, T., Franciotta, S., Marin, A., Napoli, F. D., Mauceri, V. A., Miante, S., Pilotto, E., Midena, E., & Gallo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852183 · Cited by 32
An Autopsy Case of the Marburg Variant of Multiple Sclerosis (Acute Multiple Sclerosis)
Suzuki, M., Kawasaki, H., Masaki, K., Suzuki, S. O., Terada, T., Tsuchida, T., Tokuyama, T., Kono, S., Komori, T., Baba, S., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0425 · Cited by 32
Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation
Zuo, M., Fettig, N. M., Bernier, L., Pössnecker, E., Spring, S., Pu, A., Xianjie, I., Lee, D. S., Ward, L. A., Sharma, A. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158144 · Cited by 31
Prochnow, N., Gold, R., & Haghikia, A. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.09.012 · Cited by 31
Silva, B. A., Leal, M. C., Farías, M. I., Ávalos, J. C., Besada, C. H., Pitossi, F. J., & Ferrari, C. C. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.01.010 · Cited by 31
Robinson, R. R., Dietz, A. K., Maroof, A. M., Asmis, R., & Forsthuber, T. G. (2019) · Immunotherapy · doi:10.2217/imt-2018-0153 · Cited by 33
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
Carotenuto, A., Giordano, B., Dervenoulas, G., Wilson, H., Veronese, M., Chappell, Z., Polychronis, S., Pagano, G., Mackewn, J. E., Turkheimer, F., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04533-y · Cited by 34
Regulation of neuroinflammation by B cells and plasma cells
Wang, A. A., Rojas, O. L., Lee, D. S. W., & Gommerman, J. L. (2020) · Immunological Reviews · doi:10.1111/imr.12929 · Cited by 33
Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients
Siger, M. (2022) · Clinical Neuroradiology · doi:10.1007/s00062-022-01144-3 · Cited by 32
Maheshwari, S., Dwyer, L., & Sîrbulescu, R. F. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106077 · Cited by 34
The B1-cell subpopulation is diminished in patients with relapsing–remitting multiple sclerosis
Tørring, C. W., Petersen, C. C., Bjerg, L., Kofod‐Olsen, E., Petersen, T., & Höllsberg, P. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.06.002 · Cited by 31
Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy
Mohammad, M. G., Hassanpour, M., Tsai, V. W.-W., Li, H., Ruitenberg, M. J., Booth, D. R., Serrats, J., Hart, P. H., Symonds, G., Sawchenko, P. E., et al. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010547 · Cited by 34
Diker, S., Has, A. C., Kurne, A., Göçmen, R., Oğuz, K. K., & Karabudak, R. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.08.008 · Cited by 31
Li, R., & Bar‐Or, A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029108 · Cited by 32
DiSano, K. D., Royce, D. B., Gilli, F., & Pachner, A. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01821 · Cited by 30
Neurons and T cells: Understanding this interaction for inflammatory neurological diseases
Yshii, L., Gebauer, C., Bernard‐Valnet, R., & Liblau, R. (2015) · European Journal of Immunology · doi:10.1002/eji.201545759 · Cited by 30
Kuceyeski, A. F., Vargas, W. S., Dayan, M., Monohan, E., Blackwell, C. M., Raj, A., Fujimoto, K., & Gauthier, S. A. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4165 · Cited by 30
Effects of Acupuncture on Gait of Patients with Multiple Sclerosis
Criado, M. B., Santos, M. J., Machado, J. P., Gonçalves, A. M., & Greten, H. J. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0355 · Cited by 30
Does Siponimod Exert Direct Effects in the Central Nervous System?
Kipp, M. (2020) · Cells · doi:10.3390/cells9081771 · Cited by 32
New Prospects for Ultra-High-Field Magnetic Resonance Imaging in Multiple Sclerosis
Ineichen, B. V., Beck, E., Piccirelli, M., & Reich, D. S. (2021) · Investigative Radiology · doi:10.1097/rli.0000000000000804 · Cited by 30
Acute and chronic synaptic pathology in multiple sclerosis gray matter
Vercellino, M., Marasciulo, S., Grifoni, S., Costassa, E. V., Bosa, C., Pasanisi, M. B., Crociara, P., Casalone, C., Chiò, A., Giordana, M. T., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211022174 · Cited by 30
Kee, R., Naughton, M., McDonnell, G. V., Howell, O. W., & Fitzgerald, D. C. (2022) · Biomedicines · doi:10.3390/biomedicines10102604 · Cited by 34
Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis
Kolber, P. L., Montag, S., Fleischer, V., Luessi, F., Wilting, J., Gawehn, J., Gröger, A., & Zipp, F. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7724-5 · Cited by 30
In vivo quantitative whole‐brain T1 rho MRI of multiple sclerosis
Gonyea, J. V., Watts, R., Applebee, A., Andrews, T. J., Hipko, S. G., Nickerson, J. P., Thornton, L. M., & Filippi, C. G. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24954 · Cited by 30
Back on the scent: the olfactory system in CNS demyelinating diseases
Joseph, A., & DeLuca, G. C. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312600 · Cited by 30
Relapses add to permanent disability in relapsing multiple sclerosis patients
Koch‐Henriksen, N., Sørensen, P. S., & Magyari, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103029 · Cited by 29
Oxidative injury in multiple sclerosis cerebellar grey matter
Kemp, K. C., Redondo, J., Hares, K. M., Rice, C. M., Scolding, N. J., & Wilkins, A. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.027 · Cited by 29
Novel MRI and PET markers of neuroinflammation in multiple sclerosis
Hagens, M. H. J., van Berckel, B. N. M., & Barkhof, F. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000326 · Cited by 29
Conant, K. E., Daniele, S. G., Bozzelli, P. L., Abdi, T., Edwards, A. A., Szklarczyk, A., Olchefske, I., Ottenheimer, D. J., & Maguire‐Zeiss, K. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0827-4 · Cited by 29
Nitsch, L., Petzinna, S. M., Zimmermann, J., Schneider, L. H., Krauthausen, M., Heneka, M. T., Getts, D. R., Becker, A. J., & Müller, M. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02140-z · Cited by 29
Brand, R. M., Friedrich, V., Diddens, J., Pfaller, M., de Franchis, F. R., Radbruch, H., Hemmer, B., Steiger, K., & Lehmann‐Horn, K. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001012 · Cited by 29
Imaging Cortical Damage and Dysfunction in Multiple Sclerosis
Filippi, M., Rocca, M. A., Horsfield, M. A., Hametner, S., Geurts, J. J. G., Comı, G., & Lassmann, H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1954 · Cited by 29
Self-citationBoster, A. L., Nicholas, J. A., Topalli, I., Kisanuki, Y. Y., Pei, W., Morgan-Followell, B., Kirsch, C., Racke, M. K., & Pitt, D. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1960 · Cited by 29
Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder
Kim, S. H., Kwak, K., Hyun, J., Jeong, I. H., Jo, H. ‐., Joung, A., Kim, J. H., Lee, S. H., Yun, S., Joo, J., et al. (2016) · European Journal of Neurology · doi:10.1111/ene.13011 · Cited by 29
Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts
Zurawski, J. D., & Stankiewicz, J. M. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.11.044 · Cited by 30
Puthenparampil, M., Zito, A., Pantano, G., Federle, L., Stropparo, E., Miante, S., Silvestro, G. D., Plebani, M., & Gallo, P. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518779951 · Cited by 37
Matthews, P. M., & Datta, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1032240 · Cited by 28
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis
Roy, S., Benedict, R. H. B., Drake, A. S., & Weinstock‐Guttman, B. (2016) · CNS Drugs · doi:10.1007/s40263-016-0319-6 · Cited by 30
Phosphorylation of myelin regulatory factor by PRKG2 mediates demyelination in Huntington's disease
Yin, P., Liu, Q., Pan, Y., Yang, W., Yang, S., Wei, W., Chen, X.-X., Hong, Y., Bai, D., Li, X., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949783 · Cited by 30
Animal Models of Multiple Sclerosis
Smith, P. (2021) · Current Protocols · doi:10.1002/cpz1.185 · Cited by 32
Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes
Tobin, W. O., Kalinowska, A., Weigand, S. D., Guo, Y., Tosakulwong, N., Parisi, J. E., Metz, I., Frischer, J. M., Lassmann, H., Brück, W., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012782 · Cited by 28
Self-citationUpdate on pathology of central nervous system inflammatory demyelinating diseases
Kalinowska, A., Guo, Y., & Lucchinetti, C. F. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0046 · Cited by 29
Self-citationAlterations of juxtaparanodal domains in two rodent models of CNS demyelination
Zoupi, L., Markoullis, K., Kleopa, K. A., & Karagogeos, D. (2013) · Glia · doi:10.1002/glia.22511 · Cited by 29
Martinez‐Pasamar, S., Abad, E. M., Moreno, B., de Mendizábal, N. V., Martínez‐Forero, I., García‐Ojalvo, J., & Villoslada, P. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-34 · Cited by 29
Ocrelizumab for the treatment of multiple sclerosis
Bigaut, K., Seze, J. D., & Collongues, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561284 · Cited by 29
Kasakin, M. F., Rogachev, A. D., Predtechenskaya, E. V., Zaigraev, V. J., Koval, V. V., & Pokrovsky, А. G. (2019) · MedChemComm · doi:10.1039/c9md00253g · Cited by 28
Guglielmetti, C., Levi, J., Huynh, T. L., Tiret, B., Blecha, J., Tang, R., VanBrocklin, H., & Chaumeil, M. M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259325 · Cited by 28
Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
Milo, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1002769 · Cited by 27
Guglielmetti, C., Boucneau, T., Cao, P., der Linden, A. V., Larson, P. E. Z., & Chaumeil, M. M. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116415 · Cited by 27
Angelis, F. D., Connick, P., Parker, R. A., Plantone, D., Doshi, A., John, N. A., Stutters, J., MacManus, D. G., Prados, F., Marshall, I., et al. (2020) · Efficacy and Mechanism Evaluation · doi:10.3310/eme07030 · Cited by 27
The role of commensal microflora-induced T cell responses in glaucoma neurodegeneration
Tang, J., Tang, Y., Yi, I., & Chen, D. F. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.06.002 · Cited by 28
Owens, G. P., Fellin, T. J., Matschulat, A. M., Salas, V., Schaller, K., Given, K. S., Ritchie, A. M., Navarro, A., Blauth, K., Hughes, E. G., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162731 · Cited by 27
Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells
Waid, D., Schreiner, T., Vaitaitis, G. M., Carter, J. R., Corboy, J. R., & Wagner, D. H. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.03.009 · Cited by 27
Epilepsy and associated mortality in patients with multiple sclerosis
Chou, I., Kuo, C., Tănăsescu, R., Tench, C. R., Tiley, C. G., Constantinescu, C. S., & Whitehouse, W. P. (2018) · European Journal of Neurology · doi:10.1111/ene.13821 · Cited by 27
Zivadinov, R., Ramanathan, M. K., Hagemeier, J., Bergsland, N., Ramasamy, D. P., Durfee, J., Kolb, C., & Weinstock‐Guttman, B. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101388 · Cited by 27
Zivadinov, R., & Pirko, I. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-9 · Cited by 27
Neurodegeneration in Progressive Multiple SclerosisPreprint
Campbell, G. R., & Mahad, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028985 · Cited by 27
Detection of grey matter microstructural substrates of neurodegeneration in multiple sclerosis
Krijnen, E. A., Russo, A. W., Karam, E. S., Lee, H., Chiang, F. L., Schoonheim, M. M., Huang, S. Y., & Klawiter, E. C. (2023) · Brain Communications · doi:10.1093/braincomms/fcad153 · Cited by 26
Contribution of new and chronic cortical lesions to disability accrual in multiple sclerosis
Beck, E., Mullins, W. A., Silva, J. D. S., Filippini, S., Parvathaneni, P., Maranzano, J., Morrison, M., Suto, D. J., Donnay, C. A., Dieckhaus, H., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae158 · Cited by 27
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Sabatino, J. J., Cree, B., & Hauser, S. L. (2025) · Annals of Neurology · doi:10.1002/ana.27270 · Cited by 27
Viral mouse models used to study multiple sclerosis: past and present
Libbey, J. E., & Fujinami, R. S. (2021) · Archives of Virology · doi:10.1007/s00705-021-04968-5 · Cited by 26
The Role of B Cells in Primary Progressive Multiple Sclerosis
Holloman, J. P., Axtell, R. C., Monson, N. L., & Wu, G. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.680581 · Cited by 28
Epilepsy as a predictor of disease progression in multiple sclerosis
Grothe, M., Ellenberger, D., von Podewils, F., Stahmann, A., Rommer, P. S., & Zettl, U. K. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211046739 · Cited by 26
Lee, D.-H., & Linker, R. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.677438 · Cited by 26
Further understanding of the immunopathology of multiple sclerosis: impact on future treatments
Bhise, V. V., & Dhib-Jalbut, S. S. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1191351 · Cited by 28
Kapoor, T., & Mehan, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200207100903 · Cited by 26
Jin, B., Zhang, C., Geng, Y., & Liu, M. (2020) · Mediators of Inflammation · doi:10.1155/2020/8827527 · Cited by 26
Wei, J., Moon, J., Yasumizu, Y., Zhang, L., Radassi, K., Buitrago-Pocasangre, N., Deerhake, M. E., Strauli, N. B., Chen, C.-W., Herman, A. E., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182790 · Cited by 27
Kolahdouzan, M., Futhey, N. C., Kieran, N. W., & Healy, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01657 · Cited by 26
Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis
Yeh, W. Z., Gresle, M. M., Jokubaitis, V., Stankovich, J. M., van der Walt, A., & Butzkueven, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15201 · Cited by 26
Huseby, E. S., Kamimura, D., Arima, Y., Parello, C. S. L., Sasaki, K., & Murakami, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00295 · Cited by 25
Bonnan, M. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00027 · Cited by 25
Saidha, S., & Calabresi, P. A. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514541509 · Cited by 25
Rossetti, I., Zambusi, L., Finardi, A., Bodini, A., Provini, L., Furlan, R., & Morara, S. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.07.005 · Cited by 25
A Further TWEAK to Multiple Sclerosis Pathophysiology
Nazeri, A., Heydarpour, P., Sadaghiani, S., Sahraian, M. A., Burkly, L. C., & Bar‐Or, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8490-y · Cited by 25
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature
Morille, J., Mandon, M., Rodriguez, S., Roulois, D., Léonard, S., Garcia, A., Wiertlewski, S., Page, E. L., Berthelot, L., Nicot, A. B., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200033 · Cited by 27
Metadata
- Authors
- Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M.
- Affiliations
- Mayo Clinic (US)
- Cleveland Clinic Research (US)
- Medical University of Vienna (AT)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2188-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3282172
- OpenAlex
- W2113948549
- Cited by
- 1,103
- References
- 50
- Citations by year
- 2026: 37 · 2025: 44 · 2024: 69 · 2023: 70 · 2022: 68 · 2021: 104 · 2020: 75 · 2019: 83 · 2018: 64 · 2017: 72 · 2016: 75 · 2015: 84 · 2014: 89 · 2013: 100 · 2012: 67
- FWCI
- 58.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Multiple Sclerosis Society (RG3185-B-3)
- Multiple Sclerosis Society
- National Institutes of Health (P50NS38667)
- National Institute of Neurological Disorders and Stroke (P50NS38667, P50NS038667, R01NS049577)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, cortical demyelination, inflammatory demyelination, meningeal inflammation, cortical lesions, early multiple sclerosis, white matter lesions, stereotactic biopsy, disease progression
- MeSH terms
- Biopsy, Cerebral Cortex, Humans, Inflammation, Multiple Sclerosis, Prevalence, Logistic Models, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
